ReviewCurrent osteoporosis reports2025
Treatment of Osteoporosis in Patients with Chronic Kidney Disease.
Review in Current osteoporosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Eldecalcitol in older adults with kidney vulnerability: a narrative review of risk-based use, dose adjustment, and monitoring.Clinical and experimental nephrology · 2026Review
- Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease.Journal of endocrinological investigation · 2026Review
- Blood Flow Restriction Training in Hemodialysis Patients: Clinical Benefits, Challenges, and Future Perspectives.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- Combination of Biomarkers and Novel Diagnostic Tools in the Management of Osteoporosis in Chronic Kidney Disease: An Update.Journal of clinical medicine · 2026Review
- Diagnostic Accuracy of Bone Turnover Markers in Patients With CKD: A Systematic Review and Meta-Analysis.Kidney medicine · 2026Article
- Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium.Kidney international reports · 2026Article
- High fracture risk, limited evidence: rethinking osteoporosis treatment in chronic kidney disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
- PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo discuss current evidence on the diagnosis and management of osteoporosis in patients with chronic kidney disease (CKD). RECENT
findingsOsteoporosis and fractures are prevalent in older CKD patients and associated with poor process indicators and outcomes. While osteoporosis treatment is generally similar in patients without or with CKD up to stage 3, there is still a lack of evidence to guide many areas of osteoporosis management in CKD stages 4-5. There is an urgent need to establish local multidisciplinary care pathways for CKD and dialysis patients with osteoporosis, involving nephrologists, bone specialists and fracture liaison services. Optimization of calcium and vitamin D metabolism and non-pharmacological measures including exercise and falls prevention should be considered in all patients. Withholding bone drugs solely based on glomerular filtration rates may constitute renalism (discrimination based on kidney function), which would further widen the already large treatment gap in osteoporosis. On the other hand, more evidence is needed to inform almost every aspect of anti-osteoporotic pharmacotherapy in CKD stages 4-5. The concept of choosing between antiresorptive or anabolic bone drugs based on a pre-treatment assessment of bone turnover (using biomarkers or bone biopsies), is a dogma in urgent need of critical re-evaluation. This narrative review aims to summarize our current understanding of the management of CKD-associated osteoporosis and fracture prevention in stage 4-5 CKD patients.
Indexed as
Identifiers
40457078What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.